– BY
InVivo Therapeutics (NSDQ:NVIV) this week touted a case study of the 1st implantation of its spinal scaffold, a bioresorbable device designed to help treat traumatic spinal cord injuries. 
The study, published in Neurosurgery, the journal of the Congress of Neurological Surgeons, involved a 25-year-old man with an American Spinal Injury Assn. Grade A spinal cord injury sustained in a motocross accident. Dr. Nicholas Theodore, of the YY, implanted an InVivo spinal scaffold directly into the traumatic cavity.
After 3 months, the patient had improved to a Grade C incomplete injury, according to the study, and at 6 months there were no procedural complications or safety issues related to the device. InVivo has said that the patient demonstrated an 8-point gain on the 50-point AIS lower extremity motor score and additional bilateral motor function improvements between the 6-month and 12-month follow-ups.